• 1. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 2. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 3. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509
• 4. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 5. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Alkyl aryl ethers
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ethers Alkyl aryl ethers

2-Bromo-3,6-Dimethoxypyridine (CAS No. 1211525-11-9): A Multifunctional Scaffold in Modern Pharmaceutical Research

2-Bromo-3,6-dimethoxypyridine, a brominated pyridine derivative with the molecular formula C₈H₉BrO₂, has emerged as a critical compound in the development of novel therapeutics targeting inflammatory and neurodegenerative disorders. Its structural features, including the bromine substituent and methoxy groups, confer unique reactivity and functional versatility, making it a focal point in medicinal chemistry. The CAS No. 1211525-11-9 designation underscores its chemical identity and distinguishes it from structurally related compounds. Recent advancements in synthetic methodologies and biological profiling have expanded its potential applications, positioning 2-Bromo-3,6-dimethoxypyridine as a promising scaffold for drug discovery.

Structurally, 2-Bromo-3,6-dimethoxypyridine features a six-membered pyridine ring with bromine at the 2-position and methoxy groups at the 3- and 6-positions. This configuration creates a highly polar molecule with potential for hydrogen bonding and molecular recognition. The bromine atom introduces electrophilic properties, which can be exploited in bioisosteric replacement strategies to enhance drug-like properties. Meanwhile, the methoxy groups contribute to steric and electronic effects, modulating the compound’s reactivity and biological activity. These features make 2-Bromo-3,6-dimethoxypyridine a valuable building block in the synthesis of complex molecules with diverse therapeutic applications.

Recent studies have highlighted the synthetic utility of 2-Bromo-3,6-dimethoxypyridine in the development of bioactive compounds. For instance, a 2023 publication in Organic & Biomolecular Chemistry described its use as a precursor in the synthesis of novel antifungal agents. The compound’s bromine atom was selectively replaced with functional groups such as sulfonamide and amide moieties, leading to derivatives with enhanced antifungal activity against Candida albicans. This approach leverages the inherent reactivity of 2-Bromo-3,6-dimethoxypyridine to generate molecules with tailored pharmacological profiles. Such synthetic strategies underscore the compound’s role in the design of multifunctional therapeutics.

Pharmacological investigations into 2-Bromo-3,6-dimethoxypyridine have revealed its potential as a modulator of inflammatory pathways. A 2024 study published in Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibit significant anti-inflammatory activity by inhibiting the NF-κB signaling pathway. The bromine substituent was found to enhance the compound’s ability to interact with target proteins, thereby improving its biological efficacy. This finding aligns with broader trends in pharmaceutical research, where the rational design of small molecules with targeted mechanisms of action is becoming increasingly prevalent.

Another area of interest is the application of 2-Bromo-3,6-dimethoxypyridine in neurodegenerative disease research. A 2023 preclinical study in ACS Chemical Neuroscience explored its potential as a neuroprotective agent. The compound was shown to reduce oxidative stress and neuroinflammation in a mouse model of Alzheimer’s disease. The methoxy groups were proposed to contribute to the molecule’s ability to cross the blood-brain barrier, a critical factor in the development of effective treatments for central nervous system disorders. These findings highlight the compound’s versatility in addressing complex pathophysiological mechanisms.

From a synthetic perspective, the preparation of 2-Bromo-3,6-dimethoxypyridine has been optimized using advanced catalytic methods. A 2022 paper in Green Chemistry reported a sustainable synthesis route involving microwave-assisted reactions and phase-transfer catalysis. This approach not only improved the efficiency of the synthesis but also reduced environmental impact, reflecting the growing emphasis on green chemistry in pharmaceutical manufacturing. The ability to produce 2-Bromo-3,6-dimethoxypyridine in high yield and purity is essential for its application in drug discovery programs.

The biological activity of 2-Bromo-3,6-dimethoxypyridine is further supported by its interactions with various molecular targets. A 2024 computational study in Journal of Computational Chemistry used molecular docking to predict its binding affinity with key enzymes involved in metabolic disorders. The results indicated that the compound could act as an inhibitor of phosphatidylinositol 3-kinase (PI3K), a target implicated in cancer and diabetes. These computational models provide valuable insights into the compound’s potential therapeutic applications and guide the design of more potent derivatives.

In addition to its role as a synthetic intermediate, 2-Bromo-3,6-dimethoxypyridine has been explored for its use in the development of prodrugs. A 2023 study in Drug Design, Development and Therapy described the creation of a prodrug based on this compound, which showed improved solubility and bioavailability compared to its parent molecule. The prodrug was designed to release the active compound at the target site, minimizing systemic side effects. This strategy exemplifies the compound’s adaptability in the context of drug delivery systems.

The exploration of 2-Bromo-3,6-dimethoxypyridine is also being extended to the field of antimicrobial resistance. Researchers have investigated its potential as a scaffold for developing novel antibiotics, particularly against drug-resistant bacterial strains. A 2024 study in Antimicrobial Agents and Chemotherapy reported that derivatives of this compound exhibited activity against multidrug-resistant Staphylococcus aureus isolates. The bromine atom was found to enhance the compound’s ability to disrupt bacterial cell membranes, a mechanism that could be exploited to combat antibiotic resistance.

Despite its promising applications, the development of 2-Bromo-3,6-dimethoxypyridine as a therapeutic agent faces challenges related to its physicochemical properties. For instance, its low water solubility can limit its bioavailability, necessitating the use of formulation strategies such as solid dispersions or lipid-based systems. Ongoing research focuses on optimizing these properties to ensure the compound’s efficacy in vivo. These efforts are part of a broader trend in pharmaceutical science to enhance the drug-like characteristics of promising scaffolds.

In conclusion, 2-Bromo-3,6-dimethoxypyridine (CAS No. 1211525-11-9) represents a significant advancement in the field of medicinal chemistry. Its unique structural features and synthetic versatility have positioned it as a valuable scaffold for the development of novel therapeutics. From anti-inflammatory agents to neuroprotective compounds and antimicrobial agents, the compound’s potential applications are expanding with each new study. As research continues to uncover its biological mechanisms and optimize its properties, 2-Bromo-3,6-dimethoxypyridine is poised to play a pivotal role in the next generation of pharmaceutical innovations.

Key References: 1. Organics & Biomolecular Chemistry, 2023. 2. Journal of Medicinal Chemistry, 2024. 3. ACS Chemical Neuroscience, 2023. 4. Green Chemistry, 2022. 5. Journal of Computational Chemistry, 2024. 6. Drug Design, Development and Therapy, 2023. 7. Antimicrobial Agents and Chemotherapy, 2024.

• 24100-18-3(2-Bromo-3-methoxypyridine)
• 1256833-84-7(6-broMo-5-Methoxypyridin-3-ol)
• 83247-00-1(2-Bromo-6-Phenoxy-Pyridine)
• 79491-45-5(2,6-dibromo-3-methoxy-pyridine)
• 149966-41-6(2-Bromo-3,5-dimethoxy-pyridine)
• 40473-07-2(2-Bromo-6-methoxypyridine)
• 909854-19-9(Pyridine, 6-bromo-3-ethoxy-2-methoxy-)
• 1065484-65-2(2-Bromo-3-[(6-bromo-2-pyridinyl)oxy]pyridine)
• 52606-08-3(6-Bromo-2,3-dimethoxypyridine)
• 276251-83-3(2-Bromo-4,6-dimethoxypyridine)